| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ola Gefvert, Leif H Lindström, Nicholas Waters, Susanna Waters, Arvid Carlsson, Joakim Tedrof. Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. Scandinavian journal of psychology. vol 44. issue 3. 2004-01-06. PMID:12914593. |
different corticostriatal patterns of l-dopa utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. |
2004-01-06 |
2023-08-12 |
human |
| Ola Gefvert, Leif H Lindström, Nicholas Waters, Susanna Waters, Arvid Carlsson, Joakim Tedrof. Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. Scandinavian journal of psychology. vol 44. issue 3. 2004-01-06. PMID:12914593. |
stable optimal treatment with either classical neuroleptics or clozapine partially, albeit differentially, reversed the aberrant patterns seen in drug-free schizophrenia. |
2004-01-06 |
2023-08-12 |
human |
| Ola Gefvert, Leif H Lindström, Nicholas Waters, Susanna Waters, Arvid Carlsson, Joakim Tedrof. Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. Scandinavian journal of psychology. vol 44. issue 3. 2004-01-06. PMID:12914593. |
treatment with clozapine or classical neuroleptics induces partial, albeit differential, normalization of the abnormal patterns seen in untreated schizophrenia. |
2004-01-06 |
2023-08-12 |
human |
| Douglas L Noordsy, Alan I Gree. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Current psychiatry reports. vol 5. issue 5. 2004-01-06. PMID:13678553. |
the preferential use of novel antipsychotics, a lower threshold for prescription of clozapine, the use of bupropion for smoking cessation, careful monitoring of compliance, and possible use of other medications for substance use disorders when indicated are recommended in pharmacologic management for people with co-occurring substance use disorders and schizophrenia. |
2004-01-06 |
2023-08-12 |
Not clear |
| Cyrille Sur, Pierre J Mallorga, Marion Wittmann, Marlene A Jacobson, Danette Pascarella, Jacinta B Williams, Philip E Brandish, Douglas J Pettibone, Edward M Scolnick, P Jeffrey Con. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proceedings of the National Academy of Sciences of the United States of America. vol 100. issue 23. 2004-01-05. PMID:14595031. |
the molecular and neuronal substrates conferring on clozapine its unique and superior efficacy in the treatment of schizophrenia remain elusive. |
2004-01-05 |
2023-08-12 |
human |
| B J Turner, A Rembach, R Spark, E C Lopes, S S Cheem. Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. Journal of neuroscience research. vol 74. issue 4. 2003-12-23. PMID:14598305. |
clozapine is a potent atypical neuroleptic or antipsychotic agent used to relieve symptoms of early-diagnosed schizophrenia. |
2003-12-23 |
2023-08-12 |
mouse |
| Lilly Schwieler, Sophie Erhard. Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 10. 2003-12-05. PMID:12865892. |
in the present in vivo electrophysiological study, we investigate the effects of haloperidol (a typical antipsychotic drug) and clozapine on ventral tegmental area (vta) dopamine (da) neurons in a situation of hyperdopaminergic activity in order to mimic tentatively a condition similar to that seen in schizophrenia. |
2003-12-05 |
2023-08-12 |
rat |
| Lilly Schwieler, Sophie Erhard. Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 10. 2003-12-05. PMID:12865892. |
such an effect of clozapine may be related to its unique effect in also ameliorating negative symptoms of schizophrenia. |
2003-12-05 |
2023-08-12 |
rat |
| Chen-Jee Hong, Younger W-Y Yu, Ching-Hua Lin, Shih-Jen Tsa. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neuroscience letters. vol 349. issue 3. 2003-12-04. PMID:12951204. |
the present study tested the hypothesis that the bdnf-gene val66met polymorphism is associated with schizophrenia and clozapine's therapeutic response. |
2003-12-04 |
2023-08-12 |
Not clear |
| Chen-Jee Hong, Younger W-Y Yu, Ching-Hua Lin, Shih-Jen Tsa. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neuroscience letters. vol 349. issue 3. 2003-12-04. PMID:12951204. |
our finding suggests that this bdnf-gene val66met polymorphism may be related to schizophrenia pathogenesis in patients responsive to clozapine treatment. |
2003-12-04 |
2023-08-12 |
Not clear |
| Peter Schult. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clinical pharmacokinetics. vol 42. issue 7. 2003-11-25. PMID:12844323. |
clozapine is the gold standard and 'last resort' in treatment of refractory schizophrenia. |
2003-11-25 |
2023-08-12 |
Not clear |
| M Mazza, C Tozzini, P Giosué, A De Risio, M Palmucci, R Roncone, M Casacchi. [Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study]. La Clinica terapeutica. vol 154. issue 2. 2003-11-24. PMID:12856365. |
our study was conducted in the form of naturalistic observation of a sample of 45 people affected by schizophrenia treated with haloperidol, clozapine and risperidone. |
2003-11-24 |
2023-08-12 |
Not clear |
| Stephen J Glatt, Stephen V Faraone, Ming T Tsuan. Schizophrenia is not associated with DRD4 48-base-pair-repeat length or individual alleles: results of a meta-analysis. Biological psychiatry. vol 54. issue 6. 2003-11-10. PMID:13129658. |
the gene drd4, coding for dopamine receptor d4, was considered a candidate for association with schizophrenia based on its upregulation in postmortem schizophrenic brain and affinity for clozapine. |
2003-11-10 |
2023-08-12 |
Not clear |
| Joyce G Small, Marietta H Klapper, Frederick W Malloy, Timothy M Steadma. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. Journal of clinical psychopharmacology. vol 23. issue 3. 2003-10-23. PMID:12826983. |
tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. |
2003-10-23 |
2023-08-12 |
Not clear |
| Berna Binnur Kivircik, Köksal Alptekin, Sezer Calişkan, Abdurrahman Cömlekçi, Gonca Orük, Mevhibe Tümüklü, Kablan Kürklü, Haluk Arkar, Ayşe Türk, Mehmet Calişkan, Sena Yeşi. Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 27. issue 5. 2003-10-23. PMID:12921912. |
effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. |
2003-10-23 |
2023-08-12 |
Not clear |
| M A Tanner, W Cullin. Clozapine associated dilated cardiomyopathy. Postgraduate medical journal. vol 79. issue 933. 2003-10-09. PMID:12897222. |
his only significant past medical history was of chronic schizophrenia for which he had been taking clozapine for six years. |
2003-10-09 |
2023-08-12 |
Not clear |
| Joanna Moncrief. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. The British journal of psychiatry : the journal of mental science. vol 183. 2003-09-30. PMID:12893670. |
clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. |
2003-09-30 |
2023-08-12 |
Not clear |
| Christopher D Carlson, Patrizia A Cavazzoni, Paul H Berg, Hank Wei, Charles M Beasley, John M Kan. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. The Journal of clinical psychiatry. vol 64. issue 8. 2003-09-25. PMID:12927004. |
an integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. |
2003-09-25 |
2023-08-12 |
Not clear |
| Baruch Spivak, Evgeny Shabash, Brian Sheitman, Abraham Weizman, Roberto Meste. The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. The Journal of clinical psychiatry. vol 64. issue 7. 2003-09-23. PMID:12934974. |
the effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. |
2003-09-23 |
2023-08-12 |
Not clear |
| Jan Volavk. Clozapine may be more effective than olanzapine for reducing suicidal behaviour in people with schizophrenia at high risk. Evidence-based mental health. vol 6. issue 3. 2003-09-15. PMID:12893804. |
clozapine may be more effective than olanzapine for reducing suicidal behaviour in people with schizophrenia at high risk. |
2003-09-15 |
2023-08-12 |
Not clear |